Abstract
In a prospective, randomized, double-blind, multicenter study, 202 patients with cancer from 19 medical centers were treated for hypercalcemia of malignancy with daily intravenous infusions of etidronate disodium (136 patients) or saline alone (66 patients) for 3 consecutive days. Patients also received up to 3.25 L of saline daily during the treatment period. Of 157 patients for whom data could be evaluated for efficacy, 63% (72/114) of etidronate-treated and 33% (14/43) of saline-treated patients had a normalization of total serum calcium levels. When serum calcium levels were adjusted for albumin (147 assessable patients), 24% of the etidronate- and 7% of the saline-treated patients responded to treatment. No serious side effects or treatmentrelated deaths occurred. When accompanied by adequate hydration and diuresis, intravenous etidronate was safe and more effective than hydration and diuresis alone in controlling hypercalcemia of malignancy.
| Original language | English |
|---|---|
| Pages (from-to) | 471-476 |
| Number of pages | 6 |
| Journal | Archives of Internal Medicine |
| Volume | 151 |
| Issue number | 3 |
| DOIs | |
| State | Published - 1991 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Internal Medicine
Cite this
Treatment of Hypercalcemia of Malignancy With Intravenous Etidronate : A Controlled, Multicenter Study. / the Hypercalcemia Study Group.
In: Archives of Internal Medicine, Vol. 151, No. 3, 1991, p. 471-476.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Treatment of Hypercalcemia of Malignancy With Intravenous Etidronate
T2 - A Controlled, Multicenter Study
AU - the Hypercalcemia Study Group
AU - Singer, Frederick R.
AU - Ritch, Paul S.
AU - Lad, Thomas E.
AU - Ringenberg, Q. Scott
AU - Schiller, Joan H.
AU - Recker, Robert R.
AU - Ryzen, Elisabeth
PY - 1991
Y1 - 1991
N2 - In a prospective, randomized, double-blind, multicenter study, 202 patients with cancer from 19 medical centers were treated for hypercalcemia of malignancy with daily intravenous infusions of etidronate disodium (136 patients) or saline alone (66 patients) for 3 consecutive days. Patients also received up to 3.25 L of saline daily during the treatment period. Of 157 patients for whom data could be evaluated for efficacy, 63% (72/114) of etidronate-treated and 33% (14/43) of saline-treated patients had a normalization of total serum calcium levels. When serum calcium levels were adjusted for albumin (147 assessable patients), 24% of the etidronate- and 7% of the saline-treated patients responded to treatment. No serious side effects or treatmentrelated deaths occurred. When accompanied by adequate hydration and diuresis, intravenous etidronate was safe and more effective than hydration and diuresis alone in controlling hypercalcemia of malignancy.
AB - In a prospective, randomized, double-blind, multicenter study, 202 patients with cancer from 19 medical centers were treated for hypercalcemia of malignancy with daily intravenous infusions of etidronate disodium (136 patients) or saline alone (66 patients) for 3 consecutive days. Patients also received up to 3.25 L of saline daily during the treatment period. Of 157 patients for whom data could be evaluated for efficacy, 63% (72/114) of etidronate-treated and 33% (14/43) of saline-treated patients had a normalization of total serum calcium levels. When serum calcium levels were adjusted for albumin (147 assessable patients), 24% of the etidronate- and 7% of the saline-treated patients responded to treatment. No serious side effects or treatmentrelated deaths occurred. When accompanied by adequate hydration and diuresis, intravenous etidronate was safe and more effective than hydration and diuresis alone in controlling hypercalcemia of malignancy.
UR - http://www.scopus.com/inward/record.url?scp=0025974180&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025974180&partnerID=8YFLogxK
U2 - 10.1001/archinte.1991.00400030039007
DO - 10.1001/archinte.1991.00400030039007
M3 - Article
C2 - 1900410
AN - SCOPUS:0025974180
VL - 151
SP - 471
EP - 476
JO - JAMA Internal Medicine
JF - JAMA Internal Medicine
SN - 2168-6106
IS - 3
ER -